imiloxan has been researched along with lapatinib in 1 studies
| Studies (imiloxan) | Trials (imiloxan) | Recent Studies (post-2010) (imiloxan) | Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) |
|---|---|---|---|---|---|
| 45 | 0 | 21 | 1,919 | 305 | 1,442 |
| Protein | Taxonomy | imiloxan (IC50) | lapatinib (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.375 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0827 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0537 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 8.5 | |
| D(1A) dopamine receptor | Sus scrofa (pig) | 0.06 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1659 | |
| Alpha-1A adrenergic receptor | Sus scrofa (pig) | 0.06 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
1 other study(ies) available for imiloxan and lapatinib
| Article | Year |
|---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |